How Do Molecular Alterations Guide Targeted Therapies?
Molecular profiling of tumors can identify specific alterations that guide targeted therapies. These therapies are designed to specifically inhibit the activity of mutant proteins or signaling pathways altered by these genetic changes. For instance, mutations in the EGFR gene in non-small cell lung cancer can be targeted by tyrosine kinase inhibitors like erlotinib and gefitinib.
